EC
EcoR1 Capital Portfolio holdings
AUM
$1.69B
This Quarter Return
+36.32%
1 Year Return
+7.54%
3 Year Return
+113.08%
5 Year Return
+306.58%
10 Year Return
+4,328.75%
AUM
$924M
AUM Growth
+$924M
(+6.3%)
Cap. Flow
-$175M
Cap. Flow
% of AUM
-18.9%
Top 10 Holdings %
Top 10 Hldgs %
69.3%
Holding
56
New
7
Increased
7
Reduced
13
Closed
17
Top Buys
| 1 |
CRISPR Therapeutics
CRSP
|
$59.6M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$34.5M |
| 3 |
Xencor
XNCR
|
$33.2M |
| 4 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$25.9M |
| 5 |
Gossamer Bio
GOSS
|
$16.7M |
Top Sells
| 1 |
FibroGen
FGEN
|
$73.7M |
| 2 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
$69.2M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$39.2M |
| 4 |
Ascendis Pharma
ASND
|
$37.5M |
| 5 |
Assembly Biosciences
ASMB
|
$24.6M |
Sector Composition
| 1 | Healthcare | 88.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Rocket Pharmaceuticals
RCKT
$354M
| $7.89M | 0.73% | 450,000 | – | – |
|
27
Arbutus Biopharma
ABUS
$711M
| $7.78M | 0.72% | 2,172,883 -1,108,619 | -34% | -$3.97M |
|
|
KDNY
28
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $7.72M | 0.71% | +1,939,390 | New | +$7.72M |
|
|
UBX
29
DELISTED
Unity Biotechnology
UBX
| $7.35M | 0.68% | 906,614 -60,500 | -6% | -$491K |
|
30
Scholar Rock
SRRK
$3.14B
| $6.36M | 0.59% | 338,668 -1,135,560 | -77% | -$21.3M |
|
31
Neurogene
NGNE
$264M
| $6.11M | 0.56% | 2,265,880 | – | – |
|
32
Curis
CRIS
$20.9M
| $5.94M | 0.55% | 2,982,208 | – | – |
|
33
Zai Lab
ZLAB
$3.68B
| $2.32M | 0.21% | 78,519 -490,858 | -86% | -$14.5M |
|
34
Vericel Corp
VCEL
$1.83B
| $2.29M | 0.21% | +131,001 | New | +$2.29M |
|
|
SNNA
35
DELISTED
Sienna Biopharmaceuticals, Inc.
SNNA
| $1.86M | 0.17% | +800,000 | New | +$1.86M |
|
36
Arvinas
ARVN
$568M
| $738K | 0.07% | 50,000 | – | – |
|
37
Aclaris Therapeutics
ACRS
$209M
| – | – | -613,728 | Closed | -$4.54M |
|
|
AFMD
38
DELISTED
Affimed
AFMD
| – | – | -158,221 | Closed | -$492K |
|
39
Corcept Therapeutics
CORT
$7.35B
| – | – | -166,005 | Closed | -$2.22M |
|
40
Corvus Pharmaceuticals
CRVS
$428M
| – | – | -295,420 | Closed | -$1.08M |
|
41
Dynavax Technologies
DVAX
$1.19B
| – | – | -140,118 | Closed | -$1.28M |
|
42
Gilead Sciences
GILD
$140B
| – | – | 0 | – | – |
|
|
43
Ionis Pharmaceuticals
IONS
$6.79B
| – | – | -725,326 | Closed | -$39.2M |
|
44
Nektar Therapeutics
NKTR
$568M
| – | – | 0 | – | – |
|
45
ProQR Therapeutics
PRQR
$237M
| – | – | -11,022 | Closed | -$174K |
|
46
Sangamo Therapeutics
SGMO
$157M
| – | – | -1,185,831 | Closed | -$13.6M |
|
47
Solid Biosciences
SLDB
$427M
| – | – | -867,246 | Closed | -$23.2M |
|
48
Wave Life Sciences
WVE
$1.53B
| – | – | -233,933 | Closed | -$9.84M |
|
49
Traws Pharma
TRAW
$9.89M
| – | – | -423,441 | Closed | -$893K |
|
|
CNST
50
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
| – | – | -79,194 | Closed | -$318K |
|